Experimental Dual-Target CAR-T therapy shows promise for Tough-to-Treat leukemia
NCT ID NCT04049383
First seen Jan 12, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This early-phase study tested a personalized cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on leukemia cells. It involved 5 patients with B-cell acute lymphoblastic leukemia that had returned or not responded to standard treatments. The main goal was to check safety and side effects, with the therapy made using a special closed system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.